91 results about "Airway inflammation" patented technology

The invention provides a traditional Chinese medicine composition for treating or improving asthma, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: inula flower, tabasheer, Japanese ardisia herb, cymbopogon distans, ligusticum, pyrrosia lingua, pawpaw, yam rhizome, rhizoma atractylodis, walnut meat, maltose, citron and liquorice. The monarch, minister, assistant and guide in the traditional Chinese medicine composition make the best responsibility, the traditional Chinese medicine composition aims at the symptoms of phlegm-qi obstruction and adverse rising of lung qi of asthma, also has the effects of strengthening the spleen, tonifying the kidney, soothing the liver and the like to consolidate the root cause, has the effects of dispelling wind and ventilating the lung, eliminating phlegm and lowering adverse qi, tonifying the spleen and eliminating dampness, warming the kidney and absorbing qi, and regulating the liver and regulating qi, and has the effects of purgation and tonification and treatment of both symptoms and root causes. The traditional Chinese medicine composition can effectively inhibit airway inflammation reaction of asthma model mice and improve clinical symptoms of the asthma mice, and is remarkable in treatment effect. The traditional Chinese medicine composition disclosed by the invention has a relatively high total effective rate for treating asthma, and has more advantages in the aspects of relieving clinical symptoms of asthma patients and improving lung functions.

The invention discloses application of a lysosome cathepsin L inhibitor in a medicine for treating or relieving allergic airway inflammation, and relates to the field of allergic airway inflammation. It is found through research that inflammatory response of asthma can be relieved by inhibiting expression of lysosome CTSL in macrophages and animal models; the inflammatory response of asthma can be relieved by inhibiting expression of lysosome CTSL in macrophages by using a small-molecule inhibitor and myeloid specific knockout CTSL, so that the lysosome cathepsin L inhibitor can effectively relieve allergic airway inflammation, and a new direction can be provided for research and development of drugs for treating and relieving allergic airway inflammation in the future.

The invention relates to a medical device for evaluating physiological parameters of a respiratory system, and the device comprises a sampling device which is used for collecting detected exhaled gas after a rising inflection point of carbon dioxide; the gas sensor comprises a nitric oxide sensor and a carbon dioxide sensor; the processor is used for receiving the gas signal generated by the gas sensor; the processor is configured to establish a linear expression for calculating a risk parameter R according to the detected carbon dioxide concentration and nitric oxide concentration; the linear expression of the risk parameter R is shown in the specification; wherein the parameter is set as a constant; the parameter is nitric oxide concentration; the parameter is carbon dioxide concentration; and the parameter is a nitric oxide dynamic change rate function. Compared with the prior art, the method provided by the invention provides a more comprehensive evaluation capability for airway inflammation and abnormal ventilation.

The invention relates to the technical field of traditional Chinese medicine plasters, in particular to a traditional Chinese medicine ointment for preventing relapse of infantile asthma and a preparation method thereof.The traditional Chinese medicine ointment is characterized by sequentially comprising a protective backing layer, a medicine storage layer, a controlled release film layer and an application bonding layer from top to bottom; the traditional Chinese medicine plaster provided by the invention overcomes the defect that the traditional oral traditional Chinese medicine is easily influenced by a first-pass effect and individual differences through an external transdermal administration mode, can continuously maintain efficient medicine concentration at an application part and realize long-acting slow release, and the synergistic effect of the nano micro-emulsion medicine carrying system and the controlled release film layer can realize the sustained release effect of the traditional Chinese medicine. According to the traditional Chinese medicine plaster disclosed by the invention, the stable release of effective components of the medicine is ensured, the penetration rate of the medicine on a skin barrier is also remarkably improved, so that the treatment depth and the action durability of the plaster are enhanced, and meanwhile, the traditional Chinese medicine plaster aims at the pathological mechanism of infantile asthma, relieves airway inflammation, reduces airway hyperresponsiveness and mucus secretion, and has a remarkable curative effect on infantile asthma. The acute attack frequency of asthma can be obviously reduced, and the remission period is prolonged.

The present invention discloses the use of SRT2104 in the preparation of a drug for treating bronchial asthma, and relates to the technical field of bronchial asthma treatment. The present invention comprehensively evaluates the activation effect of SRT2104 on airway epithelial SIRT1 and the relief effect on asthmatic airway inflammation under asthma conditions, confirms the effectiveness of SRT2104 in activating airway epithelial SIRT1 and controlling asthmatic airway inflammation under asthma conditions, and lays a foundation for the discovery of clinical medical targets and the development of drugs in the treatment of bronchial asthma.

The invention provides a traditional Chinese medicine composition for treating or improving asthma, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: inula flower, tabasheer, Japanese ardisia herb, cymbopogon distans, ligusticum, pyrrosia lingua, pawpaw, yam rhizome, rhizoma atractylodis, walnut meat, maltose, citron and liquorice. The monarch, minister, assistant and guide in the traditional Chinese medicine composition make the best responsibility, the traditional Chinese medicine composition aims at the symptoms of phlegm-qi obstruction and adverse rising of lung qi of asthma, also has the effects of strengthening the spleen, tonifying the kidney, soothing the liver and the like to consolidate the root cause, has the effects of dispelling wind and ventilating the lung, eliminating phlegm and lowering adverse qi, tonifying the spleen and eliminating dampness, warming the kidney and absorbing qi, and regulating the liver and regulating qi, and has the effects of purgation and tonification and treatment of both symptoms and root causes. The traditional Chinese medicine composition can effectively inhibit airway inflammation reaction of asthma model mice and improve clinical symptoms of the asthma mice, and is remarkable in treatment effect. The traditional Chinese medicine composition disclosed by the invention has a relatively high total effective rate for treating asthma, and has more advantages in the aspects of relieving clinical symptoms of asthma patients and improving lung functions.

The invention discloses application of ginkgetin in treatment of chronic pulmonary obstruction, and relates to the field of medical technical methods of ginkgetin. According to the invention, by constructing a model of cigarette extract on airway epithelial cell injury, the biflavone compound is found to have a protective effect on epithelial cell injury caused by smoking; through transcriptomics research, biflavone compounds such as ginkgetin and the like are found to have pharmacological activity of inhibiting CEBP beta protein high expression caused by cigarette extracts, so that the effect of protecting airway inflammation caused by smoking is achieved. More importantly, the ginkgetin and the glucocorticoid are jointly used, so that the treatment effect on chronic pulmonary obstruction is remarkably improved compared with that of independently using the ginkgetin and the glucocorticoid, and the ginkgetin and the glucocorticoid have wide medical application.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

The invention discloses an application of thermal sensitive Sibestein granules in treating / or preventing asthma, and belongs to the technical field of biological medicines. The invention finds that the thermal sensitive Sibestein granules can reduce the total number of cells and the number of eosinophilic granulocytes, neutrophil granulocytes and lymphocytes in asthma mice BALF, reduce the level of cell factors in asthma mice BALF and IgE in serum, reduce exudation of inflammatory substances in airway and alveolar tissues of asthma mice and infiltration of inflammatory cells, improve the lesion degree of lung tissues, and improve the curative effect of the lung tissues. The action mechanism may be related to regulation and control of MAPK / NF-kappa B signal channel related protein expression, so that inflammatory response and cell apoptosis are inhibited, and airway inflammation of mice is relieved.

The invention belongs to the technical field of medicine, and discloses an artemisia annua pollen allergen sublingual drop as well as a preparation process and application thereof.The preparation is realized through the following core processes: firstly, performing raw material screening and supercritical CO2 degreasing pretreatment on artemisia annua pollen at the full-bloom stage in North China, then performing graded ultralow-temperature freezing and crushing, and performing freeze drying to obtain the artemisia annua pollen allergen sublingual drop. The particle size D90 of the superfine powder is smaller than or equal to 4 microns; then adopting a neutral protease and pectinase composite enzymatic hydrolysis system, and combining 4 DEG C low-temperature pulse ultrasound-assisted treatment to accelerate the dissolution of allergens; carrying out tangential flow grading purification and buffer solution replacement by virtue of 100kDa and 5kDa PES (Polyether Sulfonate) ultrafiltration membranes, and introducing a compound stabilizer; and finally, performing three-stage sterile filtration, and performing encapsulation and preservation. According to the process, through multi-link collaborative optimization, the extraction efficiency and activity stability of allergens are improved, and the prepared sublingual drops have the effects of improving allergic rhinitis, allergic asthma and airway inflammation and also have excellent permeability.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The invention provides application of mesenchymal stem cell-derived small extracellular vesicles in preparation of a product for preventing and / or treating airway inflammation mainly caused by neutrophil infiltration. Human cell in-vitro experiments and mouse in-vivo experiments find and prove that MSC-sEV can be directly taken by cells, activation of a cell JAK2-STAT3 pathway is inhibited, Th17 cell polarization is inhibited, neutrophil airway inflammation is remarkably relieved, and protein of MSC-sEV plays an important role in inhibition of Th17 cell polarization. The invention provides the application of the mesenchymal stem cell-derived small extracellular vesicles to prevention and treatment of airway inflammation mainly aiming at neutrophil infiltration, has the advantages of safety and effectiveness, and provides a new medicine for clinic.

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

A method to assess the disease status, determine the mean / average control of the disease and monitor the compliance to treatment over a period of time of a respiratory disease, comprising of predicting the degree of airway inflammation and disease activity by measuring the inflammatory markers, evaluating the mucosal integrity / damage by measuring the moisture levels of the exhaled air, evaluating the breathing function and obstruction by measuring the FEV1 value, and evaluating the symptom control by determining the COPD Score.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

The present application relates to a plurality of anhydrous crystal forms of N-(3-(6-amino-5-(2-(N-methacrylamido) ethyoxyl) pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, as well as compositions, methods of preparation and methods of use thereof. These crystalline forms are useful in the treatment of diseases and disorders that are typically ameliorated by inhibition of BTK. Such diseases and disorders may include inflammation and autoimmune disorders as well as lung and respiratory tract inflammation.

The invention discloses a compound traditional Chinese medicine water decoction for protecting an airway epithelial barrier and a preparation method and application thereof, the compound traditional Chinese medicine water decoction is a water decoction of a herba epimedii and fructus ligustri lucidi medicine pair, the compound traditional Chinese medicine water decoction comprises 7-14 parts by weight of herba epimedii and 7-14 parts by weight of fructus ligustri lucidi, the herba epimedii adopts roasted herba epimedii, and the fructus ligustri lucidi adopts wine fructus ligustri lucidi. The compound traditional Chinese medicine water decoction not only can inhibit airway epithelial cell apoptosis and relieve airway epithelial injury, but also can up-regulate expression of epithelial connexin caused by inflammatory injury, so that the epithelial barrier function is improved, the airway epithelial barrier steady state is maintained, and pathogens and allergens are prevented from entering. The use and popularization of the compound traditional Chinese medicine water decoction not only contribute to preventing airway inflammation, but also can relieve the incidence and severity of chronic and refractory respiratory system diseases, and has important significance for perfecting the treatment strategy of the existing respiratory system inflammatory diseases and improving the control rate.

The invention discloses a ginkgo functional edible gel product for relieving airway inflammation and a preparation method of the ginkgo functional edible gel product. The ginkgo functional edible gel product is prepared from the following components in percentage by mass: 5.15% of ginkgo ethyl acetate extract, 8% of ginkgo RS3 type resistant starch, 2% of ginkgo polypeptide, 10% of gelatin, 15% of malt syrup, 0.19% of acidity adjusting solution and 0.3% of momordica grosvenori glucoside. According to the invention, an edible gel product is used as a carrier, and ginkgo seed ethyl acetate extract and ginkgo seed RS3 type resistant starch with functional activity of relieving airway inflammation, ginkgo seed polypeptide, low-calorie and decayed tooth-resistant momordica grosvenori glucoside and malt syrup are added as sweetening agents; according to the invention, gingko is used as a raw material to prepare an edible gel product containing gingko micromolecular active substances, resistant starch and other multi-component functional components, so that the application range of gingko resources is expanded, the utilization rate of each component of gingko is improved, and the variety of functional leisure food is enriched at the same time.

The invention belongs to the technical field of medicines, and particularly relates to application of triptolide in preparation of a medicine for preventing and / or treating ILC2-mediated allergic airway inflammatory diseases. The invention provides an application of triptolide in drugs for preventing and / or treating allergic airway inflammation ILC2 activation, eosinophilic granulocyte infiltration, airway hyperresponsiveness and lung tissue injury. In addition, in a mouse allergic airway inflammation model induced by papain and IL-33, the relieving effect of the triptolide on the ILC2-mediated airway inflammation is verified. In addition, the invention provides an important earlier-stage basis for developing a triptolide combined medicine or optimizing an administration mode, improving the bioavailability of the triptolide and reducing the toxic and side effects of the triptolide. By focusing ILC2 and exploring the effect of the traditional Chinese medicine triptolide in relieving allergic airway inflammation, a new treatment strategy is expected to be provided for allergic airway inflammation patients, and the cure rate is increased.

The invention discloses application of an inhibitor Acevaltrate targeting PCBP2 in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The invention discloses application of PCBP2 as a molecular target of a drug for treating allergic asthma. The core pathological mechanism of allergic asthma is closely related to M2 polarization of macrophages, and PCBP2 positively drives the polarization process by regulating an STAT6 signal channel. Acevaltrate can specifically inhibit the biological function of PCBP2 and block M2 polarization of macrophages induced by IL-4 / IL-13, so that airway inflammation is relieved, over-generation of IgE (immunoglobulin E) is inhibited, and airway remodeling is improved. The invention further provides a pharmaceutical composition containing the Acevaltrate, a drug combination scheme of the Acevaltrate and an existing asthma treatment drug, and a drug screening system based on a PCBP2-M2 polarization axis. The technology breaks through the limitation of an existing asthma treatment target spot, realizes the trans-boundary application of Acevaltrate from an anti-tumor drug to an anti-asthma drug, provides an accurate and efficient novel treatment strategy for allergic asthma, especially refractory asthma, and has remarkable clinical transformation value and wide application prospects.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and / or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

The invention discloses application of a reagent for detecting LSH in preparation of a chronic obstructive pulmonary disease diagnosis preparation and application of a reagent for overexpressing the LSH in preparation of a medicine for treating the chronic obstructive pulmonary disease. Protein expression of LSH in a patient suffering from the chronic obstructive pulmonary disease is found to be lower than that of healthy people and expression of pure smokers through western blot and RT-qPCR detection for the first time. Therefore, the possibility of using the LSH as the detection marker of the chronic obstructive pulmonary disease is provided. The LSH overexpression adeno-associated virus improves obstructive ventilation dysfunction and large and small airway dysfunction of a model mouse, relieves the emphysema degree, reduces the airway inflammation level and inhibits small airway remodeling, and further analysis on inflammatory cells in the lung shows that the overexpression of the LSH overexpression adeno-associated virus can reduce the proportion of pulmonary interstitial macrophages. The invention provides a new way with a prospect for treating the chronic obstructive pulmonary disease.

The present invention discloses a traditional Chinese medicine composition for treating airway inflammation and a preparation method thereof. The traditional Chinese medicine composition comprises raw materials in the following weight ratios: 32-36 parts of honey-fried ephedra, 6-10 parts of asarum, 32-36 parts of magnolia flower, 6-10 parts of perilla seed, 32-36 parts of stir-fried immature bitter orange with bran, 6-10 parts of semen lepidii, 6-10 parts of loquat leaf, 32-36 parts of wine-processed scutellaria baicalensis, 10-14 parts of semen zanthoxyli, and 6-10 parts of liquorice. The selected raw materials of the traditional Chinese medicine composition conform to the compatibility principle of "sovereign, minister, assistant, and guide". Each component synergistically or jointly functions, so that the traditional Chinese medicine composition has the effects of relieving exterior syndrome and dispersing lung qi, regulating qi and resolving phlegm, relieving cough and asthma. Looking at the whole prescription, the compatibility of various herbs is rigorous and reasonable, closely following the etiology and pathogenesis of asthma, embodying the principle of treating the symptoms first in traditional Chinese medicine, and mainly treating airway inflammations such as cold asthma syndrome, bronchial asthma, and asthmatic bronchitis, and the effect is ideal.

The invention relates to a pharmaceutical application of ginkgo tRFs targeting PMEPA1 in treatment of asthma. The PMEPA1 is an important target which is screened out through information analysis and experimental verification and participates in asthma attack, is highly expressed in asthma and is in positive correlation with airway remodeling and airway inflammation. The tRFs adopting the gingko traditional Chinese medicine can significantly inhibit PMEPA1 and relieve collagen deposition, glycogen accumulation and airway inflammation of asthma mice. The invention prompts that PMEPA1 can become a new target for asthma pharmacy, and tRFs and pharmaceutical compositions derived from ginkgo traditional Chinese medicines can become brand new medicines for treating asthma. The medicine comprises the RNA molecule and a pharmaceutically acceptable carrier, a diluent and / or an excipient. The invention is helpful to research and development of asthma treatment medicines, and provides reference for research and development of other respiratory system disease treatment medicines.

This invention belongs to the field of pharmaceutical technology. Addressing the problem that current TCM treatments for allergic rhinitis-asthma syndrome primarily rely on literature review and the experience of renowned practitioners, lacking clinically validated and fixed-composition TCM formulas, this invention proposes a TCM composition, a TCM preparation, its preparation method, and its application. The TCM composition provided by this invention is made from the following raw materials in parts by weight: Bupleurum chinense 3-10 parts, Angelica sinensis 6-15 parts, Paeonia lactiflora 6-15 parts, Magnolia biondii 6-15 parts, Cicadae periostracum 3-12 parts, Perilla frutescens 6-15 parts, Citrus reticulata 6-15 parts, Fritillaria cirrhosa 2-10 parts, Astragalus membranaceus 10-30 parts, Atractylodes macrocephala 10-30 parts, Saposhnikovia divaricata 6-12 parts, and Glycyrrhiza uralensis 3-12 parts. This invention can effectively improve the disease control level of CARAS patients, increase asthma control test scores, significantly reduce allergic rhinitis control symptom scores, significantly improve quality of life, and significantly alleviate clinical symptoms. Specifically, it promotes the recovery of disease and lung function by regulating immunity, increasing IFN-γ levels, reducing eosinophil infiltration, and improving chronic airway inflammation.

The invention relates to the technical field of medicine, in particular to application of kidney tonifying and asthma relieving decoction in treating asthma, and is technically characterized in that according to the scheme, a bronchial asthma kidney qi deficiency syndrome model is established, a pyroptosis path is utilized, and key inflammatory bodies and inflammatory body related cell factors of the pyroptosis are combined, so that the bronchial asthma kidney qi deficiency syndrome model is established. According to the invention, the mechanism of the kidney-tonifying and asthma-relieving decoction for improving asthma symptoms and intervening the development of the disease course is deeply researched, the mechanism of the kidney-tonifying and asthma-relieving decoction for regulating and controlling the pyroptosis of asthma cells and inhibiting the expression of T cell NLRP3, Caspase 1, Gasdermin family and IL-1beta through an STAT6 / GATA-3 pathway so as to improve the airway inflammation of asthma is provided, and the research on the influence of the kidney-tonifying and asthma-relieving decoction on the pyroptosis signal pathway is developed. The invention can provide a scientific basis for the application of the kidney-tonifying and asthma-relieving decoction to the treatment of asthma, further research the effective target of the kidney-tonifying and asthma-relieving decoction on the molecular level and the essential material basis of the kidney qi deficiency syndrome, and provide a theoretical basis and a new thought for revealing the pathogenesis of asthma and research on the essence of the syndrome.

The invention belongs to the technical field of nano preparations, and particularly relates to a hirudin nano drug for relieving chronic asthma and a preparation method thereof.The hirudin nano drug is prepared from, by weight, 0.5-1 part of hirudin prodrug, 10-15 parts of stabilizer, 40-80 parts of freeze-drying protective additive and 1.5 parts of histidine; the hirudin prodrug molecule is composed of hirudin, MMP-9 responsive peptide, ROS responsive thioether bond and hydrophobic hexadecanoic acid, can spontaneously assemble to form a nano-sized prodrug under hydrophilic and hydrophobic effects, has stability in systemic circulation and is targeted and enriched at an asthma airway inflammation part; the hirudin with the thrombin activity inhibition effect is responsively released at the focus, so that the effect and the purpose of slowly treating the asthma are achieved.

The invention discloses a budesonide-loaded ginseng vesicle delivery system and a construction method and application thereof, and belongs to the technical field of plant-derived nano-drug delivery systems. According to the delivery system, nano-vesicles from ginseng are taken as carriers, and budesonide is entrapped to form a BUD-coated GDNPs compound. The delivery system can synergistically enhance the anti-inflammatory effect of budesonide, significantly alleviate airway inflammation of asthma model animals, reduce side effects such as blood glucose disorder and the like caused by high-dose budesonide, and has excellent biological safety. The delivery system provided by the invention can be used for clinical treatment of asthma, is especially suitable for patients who need to use glucocorticoid for a long time, solves the technical problems of low bioavailability and obvious side effects of traditional budesonide, and has important clinical application value and industrialization prospect.

A composition is provided comprising an effective amount of a combination of gamma linolenic acid (GLA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). The composition comprises about 5% w / w to about 25% w / w GLA, and about 5% w / w to about 25% w / w of a mixture of DHA and EPA. Methods of modulating fatty acid profiles or treating an inflammatory condition in a horse include administering an effective amount of the composition to the horse. The inflammatory conditions capable of being treated include gastric ulcers, airway inflammation, joint inflammation, or combinations thereof.